The Russian retail market for veterinary drugs demonstrates stable growth with double-digit growth rates. The key factor in this dynamic is large-scale import substitution: domestic companies have surpassed imports both in the breadth of their assortment and in sales volumes.

The Russian retail market for systemic non-steroidal antirheumatic drugs (NSAIDs) has demonstrated growth in value volume for four consecutive years, recording maximum historical figures last year. However, based on the results of the first eight months of 2026, the group was characterized by a decline in physical consumption for the first time.

This year, the Russian retail market for dressing materials demonstrated a decline in physical consumption in packages against the backdrop of moderate inflationary growth in monetary terms. Nevertheless, the decline in physical demand was partially offset by a shift to larger package formats.

The Russian retail market for diuretics has encountered a significant structural change in demand, whereby, against the backdrop of overall sales growth for premium-price diuretics, physical consumption of a number of mass-market products declined for the first time in several years.

In the regional breakdown by per capita spending volumes for January–August 2026, Moscow Oblast leads, where the indicator exceeded RUB 12,400 per person, demonstrating annual growth of 12.9%.

This year, the Russian market for portable electric massagers has reached a saturation point across all key distribution channels (online and offline). At the same time, the decline in sales volumes is driven by reduced interest in unbranded products in the lower price segment.

Demand for iron supplements in Russian pharmaceutical retail has been steadily growing for the fourth consecutive year. Moreover, in April and September of this year, the category recorded a historical record for daily sales. Changes in the top ten brands in this group are also noteworthy.

In recent years, the anticoagulant segment (direct factor Xa inhibitors) has seen noticeable growth in physical sales volume. This dynamic is largely driven by rivaroxaban generics. Over the past two years, the physical share of drugs priced below RUB 1,000 in the category has grown to 39.6%.